Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Blood disorders Stories

2012-06-20 00:44:06

-An estimated 10,200 Americans will die of acute myeloid leukemia (AML) in 2012, so new ways of treating the disease are needed. -This study uses a novel class of experimental drugs to halt a process that helps AML cells develop and survive. -The findings show that the agent is promising and should be considered for clinical trials testing. A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people...

2012-06-19 10:22:52

When a North Carolina girl's body starts attacking itself out of the blue, a horse steps in to save her life WASHINGTON, June 19, 2012 /PRNewswire-USNewswire/ -- FBR Media and executive producer Frankie Trull announced today the world premiere of their made-for-television documentary "Liviya's Story" on NBC 17 (WNCN) on June 21, 2012, at 11:30 AM EDT. "Liviya's Story" is the latest episode in FBR Media's Bench to Bedside TV series. With this distinguished documentary, FBR Media brings to...

2012-06-18 23:16:24

Leukemia patients 16 to 39 have higher long-term survival rates, finds TAU researcher Acute lymphoblastic leukemia (ALL), usually found in pediatric patients, is far more rare and deadly in adolescent and adult patients. According to the National Marrow Donor Program, child ALL patients have a higher than 80 percent remission rate, while the recovery rate for adults stands at only 40 percent. In current practice, pediatric and young adult ALL patients undergo different treatment...

2012-06-18 10:24:21

Spirited 10-week fundraising competition introduced powerful new techniques to raise money for vital blood cancer research and patient services. SAN FRANCISCO, June 18, 2012 /PRNewswire-USNewswire/ -- The Greater San Francisco Bay Area Chapter of The Leukemia & Lymphoma Society (LLS) announced the results of its 22nd annual "Man & Woman of the Year" campaign - in which candidates introduced innovative fundraising techniques that garnered headlines around the world - at the Grand...

2012-06-18 05:43:06

(Ivanhoe Newswire) - NK/T-cell lymphoma is a very aggressive form of cancer, and currently has no effective treatment along with having a poor prognosis. This subtype of lymphoma is pretty rare in the United States, but is responsible for a large number of deaths in Asia, particularly China and Korea. A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a...

2012-06-17 22:22:31

AMSTERDAM, June 18, 2012 /PRNewswire/ -- The European Hematology Association (EHA), the American Society of Hematology (ASH), and the European Cancer Patient Coalition (ECPC) joined in issuing a common call to action in an effort to mitigate shortages of hematologic drugs in Europe, the United States and around the world. The collective made the announcement today following the EHA-ASH Joint Symposium at the 17th EHA Congress in Amsterdam which was dedicated to the...

2012-06-17 22:22:09

AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire/ -- ~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors ~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients ~ Data supports ARIAD filing for EMA approval of ponatinib in Europe ARIAD...

2012-06-17 22:22:04

SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine...

2012-06-17 23:03:29

The San Francisco Bay Area chapter of The Leukemia & Lymphoma Society´s (LLS) Team In Training (TNT) was represented once again during the Olympic Torch Relay. San Francisco, CA (PRWEB) June 16, 2012 The London 2012 Olympic Games begin on July 22 and the Olympic Torch Relay is currently underway. Earlier this month, San Francisco Bay Area endurance sports training and charity program, The Leukemia & Lymphoma Society´s (LLS) Team In Training (TNT), was represented once...

2012-06-16 02:20:16

AMSTERDAM, June 16, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The ibrutinib clinical updates at EHA released in two oral presentations include: 1) updated safety and efficacy data from the Phase...